Lee's Pharm In-licenses AMD Treatment from China's TOT Biopharm

Lee's Pharm has in-licensed China rights to a clinic-ready treatment for wet age-related macular degeneration developed by TOT Biopharma of Suzhou. TOT has filed an IND with the CFDA for TAB014, an injected VEGF monoclonal antibody. Lee's Pharm, which is headquartered in Hong Kong, will make upfront and milestone payments, plus pay royalties on sales. It will also be responsible for the costs of clinical development, regulatory submissions and commercialization, though no financial details were provided. More details.... Stock Symbol: (HK: 950) Share this with colleagues: // //